Reversing an Oncogenic Epithelial-to-Mesenchymal Transition Program in Breast Cancer Reveals Actionable Immune Suppressive Pathways

Reversing an Oncogenic Epithelial-to-Mesenchymal Transition Program in Breast Cancer Reveals Actionable Immune Suppressive Pathways

Approval of checkpoint inhibitors for treatment of metastatic triple negative breast cancer (mTNBC) has opened the door for the use of immunotherapies against this disease. However, not all patients with mTNBC respond to current immunotherapy approaches such as checkpoint inhibitors. Recent evidence...

Full description

Bibliographic Details
Main Authors: Michelle M. Williams, Sabrina A. Hafeez, Jessica L. Christenson, Kathleen I. O’Neill, Nia G. Hammond, Jennifer K. Richer
Format: Article
Language:English
Published: MDPI AG 2021-11-01
Series:Pharmaceuticals
Subjects:
triple negative breast cancer
epithelial-to-mesenchymal transition
immune suppression
immunotherapy
metastasis
Online Access:https://www.mdpi.com/1424-8247/14/11/1122

Internet

https://www.mdpi.com/1424-8247/14/11/1122

Similar Items